Abstract

UTIs are common in women, result in considerable morbidity and expense, and can be a vexing management problem for clinicians. We designed a randomized clinical trial study to investigate the efficacy of probiotic administration in addition to antibiotics for prevention of RUTI in women. This study was an RCT with RCT number IRCT2015090323871N1 and was approved by the Baqiyatallah University of Medical Sciences ethic committee. In this study, patients referred to the Baqiyatallah urology department with the diagnosis of UTI from April 2015 to April 2016 were included. The study 162 patients were randomized assigned in a 1:1 ratio to probiotic FamiLact capsules plus antibiotics or antibiotics alone. The intervention group was received to take one 500 mg probiotic capsule addition antibiotics every day for six month. 162 patients were evaluated for study participation. The mean ± SD age of the participants was 43.42 ± 10.85 years. In six month follow-up, 18 patients in the antibiotics alone group had the recurrence of infection and two patients in the probiotics plus antibiotics group had the recurrence of infection. In three months follow-up, 23 patients in the antibiotics alone group had the recurrence of infection and four patients in the probiotics plus antibiotics group had the recurrence of infection (P<0.001 and P<0.001 respectivly) (Table 3). There was no significant difference between two groups regarding the incidence of recurrence of infection after six follow-ups (P=0.37). Probiotics have confirmed ability to prevent and treat some infections. Efficient use of probiotics has the potential to decrease patients' exposure to antimicrobials. Available probiotics appear safe but should probably be avoided in patients at high risk for septicemia. Copyright © 2017 Oriental Scientific Publishing Company.all rights reserved.